Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that has spread to distant sites and is progressing even though testosterone remains suppressed to a castrate level. It is therefore defined by two separate facts: the cancer is metastatic, and it has become castration-resistant. Castration resistance does not mean testosterone has returned to normal, and it does not mean the cancer is resistant to every treatment. Many mCRPC tumors continue to use androgen-receptor signaling and remain treatable with hormone-pathway drugs, chemotherapy, targeted treatments, radioligand therapy or other systemic therapies.
A patient enters an mCRPC disease state when metastatic prostate cancer shows biochemical, radiographic or clinical progression despite ongoing androgen deprivation with serum testosterone maintained below the accepted castrate threshold—currently less than 50 ng/dL (1.7 nmol/L) in the EAU definition. Testosterone should therefore be checked when progression is suspected. Androgen deprivation is usually continued after mCRPC develops while additional life-prolonging treatment is selected according to previous therapy, symptoms, metastatic sites, performance status and tumor molecular profile.
01What Is Metastatic Castration-Resistant Prostate Cancer?
mCRPC combines an anatomical state with a treatment-response state
The abbreviation can be unpacked into two components:
- metastatic: distant metastatic disease is present;
- castration-resistant: the cancer is progressing despite castrate testosterone levels.
This differs from metastatic hormone-sensitive prostate cancer (mHSPC), where distant disease is present but remains responsive to initial androgen suppression.
What testosterone level defines castration resistance?
Current European guidance defines the castration-resistant state in the presence of:
serum testosterone below 50 ng/dL, equivalent to below 1.7 nmol/L.
Many men receiving effective medical androgen deprivation reach values below 20 ng/dL, but the formal CRPC threshold remains below 50 ng/dL in current guideline definitions.
Why should testosterone actually be measured?
Because a rising PSA while taking androgen-deprivation therapy does not automatically prove castration resistance.
Some men receiving medical ADT can experience:
- inadequate testosterone suppression;
- delayed injections;
- temporary testosterone breakthrough;
- or treatment-adherence problems.
If testosterone is not adequately suppressed, the immediate clinical problem may be insufficient androgen deprivation rather than true castration-resistant biology.
What counts as progression?
Progression can be recognized through several channels.
- Biochemical progression: a confirmed rising PSA pattern.
- Radiographic progression: new or enlarging metastatic lesions on imaging.
- Clinical progression: worsening cancer-related symptoms or complications.
The exact thresholds used in clinical trials are more detailed, but the key clinical principle is that progression occurs despite maintained castrate testosterone.
Is PSA progression required?
No.
Some metastatic cancers progress on imaging without a parallel PSA rise.
This is particularly important when tumor biology becomes less dependent on PSA production.
A stable PSA therefore cannot reliably substitute for:
- clinical review;
- symptom assessment;
- appropriate laboratory testing;
- and interval imaging.
What is the difference between CRPC and mCRPC?
CRPC describes castration-resistant prostate cancer regardless of whether distant metastases are present.
It can therefore be:
- nonmetastatic CRPC: no distant metastasis detected using the imaging framework being applied;
- mCRPC: metastatic disease is documented.
Can modern PSMA PET make this distinction more complicated?
Yes.
Many pivotal CRPC trials defined metastatic status with conventional imaging such as:
- CT;
- MRI;
- and bone scintigraphy.
PSMA PET/CT can detect smaller metastatic deposits earlier.
A patient called “nonmetastatic CRPC” by conventional imaging can therefore have PSMA-positive disease on a more sensitive scan.
This is an example of imaging-related stage migration and is one reason clinicians interpret modern imaging alongside the evidence base used for a specific treatment.
Does castration-resistant mean hormone-independent?
No.
This is one of the most important terminology distinctions.
Many mCRPC tumors continue to depend on androgen-receptor signaling even though ordinary testosterone suppression is no longer sufficient.
That is why therapies that further inhibit:
- androgen synthesis;
- androgen-receptor binding;
- or androgen-receptor signaling
can still work after the disease is called castration-resistant.
Does ADT stop once mCRPC develops?
Usually not.
Current guidelines continue androgen suppression because:
- the disease developed in a castrate environment;
- some cancer cells may remain androgen-responsive;
- and the major mCRPC trials studied new therapies on a background of continued castration.
The word “resistant” has a narrow meaning here. It means the cancer has escaped control by castration-level testosterone suppression. It does not mean resistance to chemotherapy, radioligand therapy, PARP inhibition, additional androgen-receptor treatment or every other anticancer strategy.
02Why Does Prostate Cancer Progress Despite Castrate Testosterone?
Prostate cancer can adapt to a low-testosterone environment
Long-term androgen suppression creates strong biological pressure on cancer cells.
Sensitive cancer cells may shrink or die, while resistant cell populations can survive and expand.
Can the androgen receptor remain active?
Yes.
Several resistance mechanisms can preserve androgen-receptor signaling.
Examples include:
- increased androgen-receptor expression;
- androgen-receptor gene amplification;
- receptor mutations;
- altered receptor splice forms;
- increased local androgen synthesis within tumor tissue;
- and activation of signaling pathways that interact with the androgen receptor.
Can mCRPC become less androgen dependent?
Yes.
Some tumors evolve toward androgen-indifferent biology.
This can include:
- aggressive-variant prostate cancer;
- treatment-emergent neuroendocrine prostate cancer;
- or other lineage-plastic states.
These forms may behave differently from ordinary androgen-receptor-driven adenocarcinoma.
When might clinicians suspect a change in tumor biology?
Features that can prompt reassessment include:
- rapid clinical progression;
- new visceral metastases;
- a large increase in tumor burden without a corresponding PSA increase;
- unusual lytic skeletal disease;
- or unexpectedly poor response to therapies aimed at the androgen receptor.
These findings do not automatically prove neuroendocrine transformation.
In selected cases, a new metastatic biopsy can help clarify the biology.
Can mCRPC spread to new organs?
Yes.
Disease can progress through:
- new bone metastases;
- enlarging lymph-node metastases;
- new lung or liver lesions;
- growth of existing metastatic sites;
- or local pelvic progression.
The underlying metastatic categories are described in Metastatic Prostate Cancer.
Why are bone metastases particularly important?
Bone remains a major disease site in mCRPC.
Complications can include:
- persistent metastatic pain;
- pathological fracture;
- vertebral collapse;
- spinal cord compression;
- and bone-marrow compromise in extensive disease.
See Bone Metastases From Prostate Cancer for the skeletal complications in detail.
mCRPC is not one molecular disease. Two patients with the same M1 stage and similar PSA can have different resistance mechanisms, prior drug exposure, genomic alterations and metastatic patterns. This is why treatment sequencing increasingly depends on biomarkers and treatment history rather than one universal drug order.
03How Is mCRPC Treated and Why Does Previous Therapy Matter?
There is no single first treatment that fits every mCRPC patient
The modern treatment decision begins with several questions:
- What treatments were already used during mHSPC?
- Has the patient received an androgen-receptor pathway inhibitor?
- Has docetaxel already been used?
- Where is the cancer currently located?
- Is the patient symptomatic?
- How fit is the patient for chemotherapy?
- Does the tumor have an actionable molecular alteration?
- Is the disease sufficiently PSMA-positive for radioligand treatment?
Why has mHSPC treatment changed the mCRPC pathway?
Historically, many men entered mCRPC having received only ADT.
Today, many patients have already received:
- abiraterone;
- enzalutamide;
- apalutamide;
- darolutamide;
- docetaxel;
- or combinations
during the hormone-sensitive metastatic phase.
The later mCRPC treatment cannot be planned without knowing those previous exposures.
Should ADT continue?
Yes, in most patients.
Castrate testosterone is generally maintained while additional life-prolonging therapy is introduced.
When can docetaxel be used?
Docetaxel remains an established life-prolonging treatment for men with mCRPC who:
- are suitable for cytotoxic chemotherapy;
- have not already exhausted its role;
- and have a disease context in which chemotherapy is appropriate.
What is cabazitaxel?
Cabazitaxel is another taxane chemotherapy with activity after docetaxel.
It is particularly important when a patient has:
- received docetaxel;
- received an androgen-receptor pathway inhibitor;
- and then experienced relatively rapid progression.
Randomized evidence from the CARD trial showed that in the relevant previously treated population, cabazitaxel was more effective than simply switching from one androgen-receptor pathway inhibitor to another.
Why can switching from one AR pathway drug to another have limited benefit?
Abiraterone, enzalutamide and related therapies all affect the androgen-receptor axis.
Resistance to one can create biological cross-resistance to another.
For this reason, repeated AR-pathway sequencing—such as changing from one closely related agent directly to another—may provide limited benefit in some mCRPC patients.
Why is molecular testing important?
Current EAU guidance recommends molecular assessment in mCRPC if it has not already been performed.
Testing can include:
- tumor or circulating-tumor DNA testing;
- germline genetic testing where appropriate;
- homologous-recombination repair genes;
- BRCA1 and BRCA2;
- and mismatch-repair or microsatellite-instability testing.
How do BRCA and other HRR alterations affect treatment?
Some mCRPC tumors have pathogenic alterations in DNA-repair pathways.
These can create sensitivity to PARP inhibition.
Depending on:
- the specific gene;
- previous ARPI exposure;
- previous chemotherapy;
- local drug approval;
- and patient fitness,
treatment can involve a PARP inhibitor alone or, in selected first-line mCRPC settings, a PARP inhibitor combined with an androgen-receptor pathway agent.
For inherited implications of BRCA variants, see BRCA1, BRCA2 and Prostate Cancer.
Why should germline and somatic results be distinguished?
A tumor mutation can be confined to the cancer.
A germline pathogenic variant is inherited and exists throughout the person’s cells.
A germline finding may therefore:
- affect treatment selection;
- change future cancer-risk counseling;
- and have implications for biological relatives.
Can immunotherapy be used?
Checkpoint immunotherapy is not a routine treatment for every mCRPC patient.
It may be clinically relevant for selected tumors with biomarkers such as:
- mismatch-repair deficiency;
- microsatellite instability;
- or another approved immunotherapy biomarker in the applicable jurisdiction.
What is PSMA radioligand therapy?
PSMA-targeted radioligand therapy uses a therapeutic radioactive isotope attached to a molecule that binds prostate-specific membrane antigen.
The best established agent is lutetium-177 PSMA-617.
Eligibility depends on:
- the pattern and intensity of PSMA expression on diagnostic imaging;
- previous systemic therapy;
- whether clinically important non-PSMA-avid disease is present;
- blood counts;
- kidney function;
- and regulatory indication.
Is lutetium-177 PSMA used only after chemotherapy?
Not universally anymore.
Treatment eligibility depends on jurisdiction and prior therapy.
Evidence now supports selected PSMA-positive mCRPC patients after androgen-receptor pathway therapy in settings where taxane chemotherapy has already been used, as well as selected patients in whom delaying taxane chemotherapy is considered appropriate under applicable approvals.
What is radium-223?
Radium-223 is a bone-seeking alpha-emitting radiopharmaceutical.
It can be useful in carefully selected mCRPC patients with:
- bone-predominant metastatic disease;
- no clinically relevant visceral metastases;
- and an appropriate treatment history.
Bone protection is important because fracture risk can increase with certain treatment combinations.
What about denosumab or zoledronic acid?
These drugs are used to reduce skeletal complications in selected men with mCRPC and bone metastases.
They are not replacements for systemic anticancer therapy.
Their use requires attention to:
- calcium;
- vitamin D;
- dental health;
- osteonecrosis-of-the-jaw risk;
- and kidney function for zoledronic acid.
How can treatment options be summarized?
| Treatment class | Examples | Clinical setting | Important selection issue |
|---|---|---|---|
| Continued androgen suppression | GnRH agonist/antagonist or prior orchiectomy | Background treatment throughout mCRPC | Maintain castrate testosterone. |
| Androgen-receptor pathway treatment | Abiraterone, enzalutamide in appropriate settings | Selected mCRPC depending on prior exposure | Benefit can be limited if a closely related pathway drug was already used. |
| Taxane chemotherapy | Docetaxel; cabazitaxel after prior docetaxel | Fit patients requiring chemotherapy | Prior mHSPC treatment and rate of progression matter. |
| PARP-directed therapy | PARP inhibitor monotherapy or selected ARPI-PARP combinations | Biomarker-selected HRR/BRCA-altered disease | Exact gene, previous therapy, toxicity and jurisdiction matter. |
| PSMA radioligand therapy | Lutetium-177 PSMA-617 | Selected PSMA-positive mCRPC | Requires appropriate PSMA expression, prior-treatment context and adequate organ function. |
| Bone-directed radiopharmaceutical | Radium-223 | Selected bone-predominant mCRPC without visceral disease | Not appropriate for every M1b patient; bone protection and treatment sequence matter. |
| Checkpoint immunotherapy | Biomarker-selected immunotherapy | Selected MMR-deficient/MSI-high or other qualifying tumors | Requires the relevant predictive biomarker and applicable approval. |
| Skeletal protection | Denosumab or zoledronic acid | Selected bone-metastatic mCRPC | Reduces skeletal events; does not replace anticancer therapy. |
| Palliative/local therapy | External-beam radiation, orthopedic or spinal treatment | Painful, unstable or threatening metastatic sites | Chosen according to symptoms and anatomical risk. |
The correct mCRPC treatment is often determined by what came before. A patient who already received an AR-pathway agent and docetaxel during hormone-sensitive disease enters mCRPC with a very different treatment menu from a patient who previously received ADT alone.
04How Is mCRPC Progression Monitored and When Is Treatment Changed?
PSA remains useful—but PSA alone is not enough
PSA is commonly followed because it can reflect disease activity.
However, mCRPC may progress:
- radiographically without a major PSA rise;
- clinically despite relatively stable PSA;
- or through changes at metastatic sites that PSA does not adequately represent.
What should follow-up include?
Depending on the treatment, follow-up can include:
- symptoms and physical function;
- PSA;
- serum testosterone;
- full blood count;
- kidney function;
- liver function;
- alkaline phosphatase;
- and interval imaging.
Treatment-specific monitoring is added for:
- chemotherapy toxicity;
- blood pressure;
- electrolytes;
- bone health;
- cardiovascular risk;
- and other known adverse effects.
How often are men with metastatic disease reviewed?
Intervals are individualized according to:
- therapy;
- symptoms;
- disease burden;
- risk of complications;
- and treatment toxicity.
Current EAU guidance recommends that M1 patients receive follow-up at least every three to six months, with regular imaging; active chemotherapy or other intensive treatment often requires more frequent review.
Can treatment be changed because PSA rises once?
Usually not on that information alone.
A PSA rise can be important, but stopping an otherwise beneficial treatment purely because of PSA progression can be misleading.
Clinicians integrate:
- PSA behavior;
- radiographic progression;
- clinical deterioration;
- treatment tolerability;
- and whether the patient is still deriving meaningful benefit.
Can bone imaging look worse even when treatment is working?
Yes.
A bone scan can show a temporary flare phenomenon after treatment.
Healing can make previously subtle skeletal lesions appear more active.
Likewise, increased sclerosis on CT can reflect treatment-related bone healing rather than tumor progression.
The imaging nuances are discussed in Bone Metastases From Prostate Cancer.
Why does symptom monitoring matter?
Metastatic disease can cause complications that need intervention before routine laboratory results change substantially.
Symptoms can include:
- new focal bone pain;
- progressive fatigue;
- weight loss;
- urinary obstruction;
- leg swelling from pelvic disease;
- new neurological symptoms;
- or declining mobility.
New or rapidly worsening back pain with leg weakness, numbness, difficulty walking, saddle-area sensory change or new bladder/bowel dysfunction requires urgent assessment. In a patient with metastatic prostate cancer, these symptoms can indicate spinal cord or cauda-equina compression and may require emergency MRI, corticosteroid treatment, radiation and/or surgical intervention.
How are skeletal complications reduced?
For men with mCRPC and bone metastases, management can include:
- effective systemic cancer treatment;
- radiation for painful lesions;
- denosumab or zoledronic acid in selected patients;
- orthopedic stabilization for impending or completed fracture;
- spinal stabilization or decompression when indicated;
- and monitoring of calcium, vitamin D and general bone health.
Why are quality-of-life issues part of cancer treatment?
Men can live with advanced prostate cancer through multiple lines of therapy.
Treatment planning therefore needs to account for:
- fatigue;
- muscle loss;
- sexual dysfunction;
- hot flashes;
- metabolic effects;
- cardiovascular risk;
- bone loss;
- pain;
- mood;
- sleep;
- and independence in daily life.
Is palliative care only for the final stage of illness?
No.
Supportive and palliative care can be integrated alongside life-prolonging therapy.
It can help manage:
- pain;
- fatigue;
- constipation;
- nausea;
- appetite loss;
- psychological distress;
- and family or caregiving needs.
Receiving palliative support does not mean anticancer treatment has stopped.
Monitoring should answer two questions simultaneously: is the cancer still being controlled, and is the treatment still tolerable enough to provide a net clinical benefit? A rising PSA is important, but imaging, symptoms, organ function and quality of life prevent treatment decisions from being reduced to one laboratory number.
↔mHSPC vs mCRPC vs Nonmetastatic CRPC
| Disease state | Metastases present? | Response to castrate testosterone environment | Core clinical distinction |
|---|---|---|---|
| mHSPC / mCSPC | Yes | Still hormone-sensitive | Metastatic disease responds to androgen suppression; modern treatment usually intensifies ADT with additional therapy. |
| nmCRPC | No metastases detected under the imaging framework used | Castration-resistant | PSA progression occurs despite castrate testosterone, but distant metastases are not demonstrated. |
| mCRPC | Yes | Castration-resistant | Metastatic disease progresses despite maintained castrate testosterone. |
| Metastatic progression without PSA rise | Yes | Can occur in mCRPC | Imaging or symptoms show progression even though PSA remains relatively stable. |
| Treatment-emergent neuroendocrine/aggressive variant | May be metastatic | Can become less AR-dependent | Requires specialist reassessment; pathology and treatment approach may differ from ordinary prostate adenocarcinoma. |
?Common Questions About mCRPC
| Question | Practical answer |
|---|---|
| What does mCRPC stand for? | Metastatic castration-resistant prostate cancer. |
| What defines mCRPC? | Documented metastatic prostate cancer that progresses despite castrate testosterone levels. |
| What testosterone level is considered castrate? | Current EAU CRPC definitions use less than 50 ng/dL, or less than 1.7 nmol/L. |
| Does castration-resistant mean testosterone is high? | No. The cancer is progressing even though testosterone remains very low. |
| Should testosterone be checked when progression is suspected? | Yes. Inadequate testosterone suppression should be excluded before calling the disease castration-resistant. |
| Does castration-resistant mean hormone treatments cannot work? | No. Many mCRPC tumors remain dependent on androgen-receptor signaling and can respond to additional AR-pathway treatment. |
| Is mCRPC the same as metastatic prostate cancer? | mCRPC is a specific metastatic state in which the cancer is progressing despite castrate testosterone. Metastatic hormone-sensitive disease has not yet reached that state. |
| What is the difference between mHSPC and mCRPC? | Both are metastatic. mHSPC remains sensitive to androgen suppression; mCRPC progresses despite it. |
| What is the difference between CRPC and mCRPC? | CRPC can be nonmetastatic or metastatic. mCRPC specifically includes documented distant metastases. |
| Does PSA have to rise for mCRPC to progress? | No. Radiographic or clinical progression can occur without a substantial PSA rise. |
| Can mCRPC spread to bone? | Yes. Bone is a major metastatic site in advanced prostate cancer. |
| Can mCRPC spread to liver or lung? | Yes. Visceral metastases can occur and can influence prognosis and treatment selection. |
| Does ADT stop when mCRPC develops? | Usually no. Castrate testosterone is generally maintained while additional treatment is given. |
| Can docetaxel treat mCRPC? | Yes, particularly in chemotherapy-appropriate patients whose previous treatment history makes docetaxel an appropriate next option. |
| What is cabazitaxel? | A taxane chemotherapy with proven activity after docetaxel, particularly in appropriately selected previously treated mCRPC. |
| Why not simply switch from abiraterone to enzalutamide or vice versa? | Cross-resistance can limit the benefit of sequential androgen-receptor pathway drugs, especially after rapid progression on the first agent. |
| Why is BRCA testing important? | BRCA1/2 and other homologous-recombination repair alterations can identify patients who may benefit from PARP-directed treatment. |
| Why is germline testing important? | An inherited pathogenic variant may affect treatment and can also have implications for relatives. |
| Can a blood test be used for tumor genetics? | Circulating-tumor DNA can sometimes identify actionable somatic alterations, although tumor tissue and germline testing may still be needed. |
| What is PSMA radioligand therapy? | A systemic radiopharmaceutical treatment that delivers radiation to PSMA-expressing prostate-cancer sites in selected patients. |
| Does everyone with mCRPC qualify for lutetium-177 PSMA? | No. PSMA imaging, prior treatment, non-PSMA-avid disease, organ function and local regulatory criteria matter. |
| Can radium-223 treat mCRPC? | It can be used in selected bone-metastatic disease without clinically relevant visceral metastases, depending on treatment history and local guidance. |
| Can immunotherapy be used? | Only in selected molecular contexts, such as qualifying mismatch-repair-deficient or microsatellite-unstable tumors. |
| Does a rising PSA automatically mean treatment should change? | No. PSA should be integrated with imaging, symptoms, clinical benefit and treatment tolerance. |
| Can imaging show progression before PSA rises? | Yes. This is why regular clinical and imaging assessment remains important in metastatic disease. |
| Can mCRPC be cured? | Distant mCRPC is generally treated as a systemic disease requiring sequential long-term control rather than assumed curable with one local treatment. |
| Can mCRPC still respond to several treatment lines? | Yes. Multiple life-prolonging treatment classes are available, and response varies according to tumor biology and prior exposure. |
| What determines prognosis? | Metastatic burden and sites, symptoms, tumor biology, genomic profile, PSA behavior, performance status, treatment history and response all contribute. |
ΣKey Clinical Takeaways
- mCRPC means metastatic castration-resistant prostate cancer.
- It combines an M1 metastatic state with progression despite castrate testosterone.
- Current EAU guidance uses testosterone below 50 ng/dL, or below 1.7 nmol/L, for the CRPC definition.
- Testosterone should be measured when castration resistance is suspected.
- A rising PSA during ADT does not prove CRPC if testosterone is not adequately suppressed.
- Progression can be biochemical, radiographic or clinical.
- Radiographic progression can occur without a substantial PSA rise.
- mHSPC and mCRPC are both metastatic states.
- mHSPC remains sensitive to initial androgen suppression.
- mCRPC progresses despite castrate testosterone.
- CRPC can exist without conventional-imaging metastases.
- More sensitive PSMA imaging can detect metastatic deposits earlier and complicate older nonmetastatic terminology.
- Castration-resistant does not mean resistant to all hormone-pathway therapy.
- Many mCRPC tumors remain driven by androgen-receptor signaling.
- Resistance mechanisms can include androgen-receptor amplification, mutation, splice variants and altered local androgen biology.
- Some tumors evolve toward less androgen-dependent or treatment-emergent neuroendocrine biology.
- Rapid progression with unexpectedly low PSA can prompt reassessment of tumor biology.
- ADT is generally continued after mCRPC develops.
- The next treatment depends heavily on therapies already received during mHSPC.
- Docetaxel remains an established mCRPC treatment.
- Cabazitaxel has an important role after prior docetaxel and selected AR-pathway treatment.
- Repeated sequencing of similar androgen-receptor pathway therapies can have limited benefit because of cross-resistance.
- Current mCRPC care should include molecular testing when not previously performed.
- Somatic and germline findings can both affect treatment.
- BRCA1, BRCA2 and other HRR alterations can identify candidates for PARP-directed treatment.
- Mismatch-repair or microsatellite-instability testing can identify a small subgroup for whom immunotherapy may be relevant.
- PSMA PET can function as a treatment-selection test as well as an imaging study.
- Lutetium-177 PSMA-617 is an important life-prolonging option for selected PSMA-positive mCRPC.
- Eligibility for PSMA radioligand therapy depends on prior treatment, scan findings and regulatory setting.
- Radium-223 is a specialized bone-directed radiopharmaceutical rather than a treatment for every metastatic site.
- Bone-directed antiresorptive drugs can reduce skeletal complications in selected bone-metastatic mCRPC.
- Denosumab and zoledronic acid do not replace systemic anticancer treatment.
- Bone metastases can cause pain, pathological fracture and spinal cord compression.
- New back pain with weakness, numbness, walking difficulty or bladder/bowel dysfunction is an urgent neurological warning sign.
- PSA alone is insufficient for monitoring mCRPC.
- Imaging, symptoms and organ function must be integrated with PSA.
- Bone-scan flare and treatment-related sclerosis can complicate imaging interpretation.
- A treatment should not automatically be stopped solely because of one PSA increase.
- Quality of life and treatment toxicity matter throughout sequential therapy.
- Supportive and palliative care can be used alongside life-prolonging treatment.
- No single universal treatment sequence fits every patient with mCRPC.
Clinical bottom line: metastatic castration-resistant prostate cancer is not defined simply by a high PSA or by the presence of metastases. It is the combination of documented metastatic disease and cancer progression despite maintained castrate testosterone. That distinction matters because androgen suppression is usually continued, while the next treatment is selected from several life-prolonging classes according to what the patient already received, where the cancer is progressing, how fit the patient is and which molecular targets are present. Modern mCRPC care can involve chemotherapy, additional androgen-receptor treatment, PARP-directed therapy, PSMA radioligand therapy, selected bone-directed radiopharmaceutical treatment and supportive skeletal care. The correct sequence is individualized rather than fixed.
Medical disclaimer: This article provides general medical education about metastatic castration-resistant prostate cancer. Drug eligibility, sequence, combinations and monitoring depend on prior treatment, metastatic sites, symptoms, blood counts, kidney and liver function, testosterone level, genomic findings, PSMA imaging, overall fitness and local regulatory approvals. Treatment decisions should be made with a specialist multidisciplinary prostate-cancer team.
For the disease state immediately before castration resistance, review Metastatic Hormone-Sensitive Prostate Cancer. For the broader anatomy and patterns of M1 spread, see Metastatic Prostate Cancer, Bone Metastases From Prostate Cancer and Advanced Prostate Cancer. For the anatomical staging framework, review Prostate Cancer Stages. For inherited DNA-repair biology relevant to selected targeted treatments, see BRCA1, BRCA2 and Prostate Cancer. For PSA behavior during progressive disease, review PSA Testing and PSA Doubling Time. For the complete disease framework, return to the Prostate Cancer hub. The next guide explains prostate cancer prognosis, including how stage, Grade Group, PSA, metastatic disease and treatment response affect expected outcomes without reducing an individual patient to a single survival number.
Evidence Sources
- European Association of Urology — Prostate Cancer Treatment: current 2026 guidance for metastatic castration-resistant prostate cancer, treatment sequencing, chemotherapy, PARP inhibitors, PSMA radioligand therapy, radium-223 and skeletal-event prevention.
- European Association of Urology — Prostate Cancer Follow-up: testosterone confirmation, PSA limitations, imaging, metastatic follow-up and monitoring during androgen-deprivation treatment.
- European Association of Urology — Classification and Staging Systems: TNM metastatic categories and the distinction between anatomical stage and biological disease state.
- EAU Patient Information — Advanced Metastatic Prostate Cancer: patient-facing information on systemic treatment, chemotherapy, targeted treatment, radiopharmaceutical therapy and supportive care.
- National Cancer Institute — Prostate Cancer Treatment, Health Professional Version: treatment of hormone-resistant and metastatic prostate cancer.
- National Cancer Institute — Prostate Cancer Treatment PDQ for Patients: advanced and metastatic treatment options.
- National Cancer Institute — Hormone Therapy for Prostate Cancer: androgen suppression, treatment resistance and advanced prostate-cancer treatment principles.
